Form 4: Assembly Biosciences Director Receives Stock Option Grant

Director Anthony E. Altig was granted 8,000 stock options in Assembly Biosciences, Inc. as part of a standard equity incentive.

Summary

• Director Anthony E. Altig received a grant of 8,000 stock options for Assembly Biosciences, Inc. (ASMB) common stock.
• The options have an exercise price of $24.11 per share.
• The grant date for the options is June 4, 2026, with an expiration date of June 4, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is dependent on the future market performance of ASMB stock exceeding the $24.11 strike price.

Future Outlook

The options vest on the earlier of June 4, 2027, or the date of the 2027 annual meeting of stockholders, assuming continuous service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board alignment with long-term strategic goals.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for small-cap biotechnology firms.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon potential future exercise of options.

Next Steps

• Vesting of options on June 4, 2027, or the 2027 annual meeting date.

Key Dates

Keywords

ASMB, Assembly Biosciences, Form 4, Insider Trading, Stock Options, Director Compensation